Chemoradiation plus dual immunotherapy for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of small cell lung cancer.
- Your cancer must be stage II or III (not spread far).
- You must not have had any prior chemotherapy, radiation, surgery, or immunotherapy for this cancer.
- You must be physically well enough to carry out daily activities (WHO score 0 or 1).
- You must not have significant autoimmune diseases or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Hear when a new Small-Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.